The primary objective of the clinical trial is to compare growth in infants (expressed as weight gain in g/day) consuming a new Amino Acid Formula to infants consuming a commercially available hypoallergenic formula over a period of 4 months.

Inclusion Criteria:

• Healthy newborn infant
• Full-term (>= 37 weeks gestation)
• Birth weight between >= 2500 and < =4500 g
• 0-17 days of age on enrolment (day 0 is day of birth)
• Infant's mother has elected not to breastfeed and to exclusively formula-feed infant
• Study explained and written information provided with Caregiver demonstrating understanding of the given information
• Informed consent signed (parent/legal representative)

Exclusion Criteria:

• Congenital illness or malformation that may affect infant feeding and/or normal growth
• Suspected or known allergy to cow's milk protein
• Significant pre-natal and/or post-natal disease
• Any readmission to hospital (except for hyperbilirubinemia) prior to enrolment
• Infant receiving prescription medication (with exception of topical antibiotics and/or treatment for thrush) or frequent use of over the counter medications except vitamin and mineral supplements
• Infant currently participating in another conflicting clinical study
• Infant's family who in the Investigator's assessment cannot be expected to comply with the protocol